Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 509 word(s) 509 2020-12-15 07:32:09

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Xu, R. Multicentric Osteolysis, Nodulosis, and Arthropathy. Encyclopedia. Available online: (accessed on 11 December 2023).
Xu R. Multicentric Osteolysis, Nodulosis, and Arthropathy. Encyclopedia. Available at: Accessed December 11, 2023.
Xu, Rita. "Multicentric Osteolysis, Nodulosis, and Arthropathy" Encyclopedia, (accessed December 11, 2023).
Xu, R.(2020, December 23). Multicentric Osteolysis, Nodulosis, and Arthropathy. In Encyclopedia.
Xu, Rita. "Multicentric Osteolysis, Nodulosis, and Arthropathy." Encyclopedia. Web. 23 December, 2020.
Multicentric Osteolysis, Nodulosis, and Arthropathy

Multicentric osteolysis, nodulosis, and arthropathy (MONA) describes a rare inherited disease characterized by a loss of bone tissue (osteolysis), particularly in the hands and feet. MONA includes a condition formerly called nodulosis-arthropathy-osteolysis (NAO) syndrome. It may also include a similar disorder called Torg syndrome, although it is unknown whether Torg syndrome is actually part of MONA or a separate disorder caused by a mutation in a different gene.

genetic conditions

1. Introduction

In most cases of MONA, bone loss begins in the hands and feet, causing pain and limiting movement. Bone abnormalities can later spread to other areas of the body, with joint problems (arthropathy) occurring in the elbows, shoulders, knees, hips, and spine. Most people with MONA develop low bone mineral density (osteopenia) and thinning of the bones (osteoporosis) throughout the skeleton. These abnormalities make bones brittle and more prone to fracture. The bone abnormalities also lead to short stature.

Many affected individuals develop subcutaneous nodules, which are firm lumps of noncancerous tissue underneath the skin, especially on the soles of the feet. Some affected individuals also have skin abnormalities including patches of dark, thick, and leathery skin. Other features of MONA can include clouding of the clear front covering of the eye (corneal opacity), excess hair growth (hypertrichosis), overgrowth of the gums, heart abnormalities, and distinctive facial features that are described as "coarse."

2. Frequency

MONA is rare; its prevalence is unknown. This condition has been reported in multiple populations worldwide.

3. Causes

MONA results from mutations in the MMP2 gene. This gene provides instructions for making an enzyme called matrix metallopeptidase 2, whose primary function is to cut (cleave) a protein called type IV collagen. Type IV collagen is a major structural component of basement membranes, which are thin, sheet-like structures that separate and support cells in many tissues. The activity of matrix metallopeptidase 2 appears to be important for a variety of body functions, including bone remodeling, which is a normal process in which old bone is broken down and new bone is created to replace it.

The MMP2 gene mutations that cause MONA completely eliminate the activity of the matrix metallopeptidase 2 enzyme, preventing the normal cleavage of type IV collagen. It is unclear how a loss of enzyme activity leads to the specific features of MONA. Researchers suspect that it somehow disrupts the balance of new bone creation and the breakdown of existing bone during bone remodeling, resulting in a progressive loss of bone tissue. How a shortage of matrix metallopeptidase 2 leads to the other features of MONA, such as subcutaneous nodules and skin abnormalities, is unknown.

4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

5. Other Names for This Condition

  • Al-Aqeel Sewairi syndrome
  • hereditary multicentric osteolysis
  • MONA
  • NAO syndrome
  • nodulosis-arthropathy-osteolysis syndrome
  • Torg syndrome
  • Torg-Winchester syndrome


  1. Al Aqeel A, Al Sewairi W, Edress B, Gorlin RJ, Desnick RJ, Martignetti JA.Inherited multicentric osteolysis with arthritis: a variant resembling Torgsyndrome in a Saudi family. Am J Med Genet. 2000 Jul 3;93(1):11-8.
  2. Al-Mayouf SM, Majeed M, Hugosson C, Bahabri S. New form of idiopathicosteolysis: nodulosis, arthropathy and osteolysis (NAO) syndrome. Am J Med Genet.2000 Jul 3;93(1):5-10. Review.
  3. Castberg FC, Kjaergaard S, Mosig RA, Lobl M, Martignetti C, Martignetti JA,Myrup C, Zak M. Multicentric osteolysis with nodulosis and arthropathy (MONA)with cardiac malformation, mimicking polyarticular juvenile idiopathic arthritis:case report and literature review. Eur J Pediatr. 2013 Dec;172(12):1657-63. doi: 10.1007/s00431-013-2102-8.
  4. Evans BR, Mosig RA, Lobl M, Martignetti CR, Camacho C, Grum-Tokars V,Glucksman MJ, Martignetti JA. Mutation of membrane type-1 metalloproteinase,MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchestersyndrome. Am J Hum Genet. 2012 Sep 7;91(3):572-6. doi:10.1016/j.ajhg.2012.07.022.
  5. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, ShethKV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ.Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentricosteolysis and arthritis syndrome. Nat Genet. 2001 Jul;28(3):261-5.
  6. Rouzier C, Vanatka R, Bannwarth S, Philip N, Coussement A, Paquis-Flucklinger V, Lambert JC. A novel homozygous MMP2 mutation in a family with Winchestersyndrome. Clin Genet. 2006 Mar;69(3):271-6.
  7. Tuysuz B, Mosig R, Altun G, Sancak S, Glucksman MJ, Martignetti JA. A novelmatrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects.Eur J Hum Genet. 2009 May;17(5):565-72. doi: 10.1038/ejhg.2008.204.
  8. Zankl A, Bonafé L, Calcaterra V, Di Rocco M, Superti-Furga A. Winchestersyndrome caused by a homozygous mutation affecting the active site of matrixmetalloproteinase 2. Clin Genet. 2005 Mar;67(3):261-6.
  9. Zankl A, Pachman L, Poznanski A, Bonafé L, Wang F, Shusterman Y, Fishman DA,Superti-Furga A. Torg syndrome is caused by inactivating mutations in MMP2 and isallelic to NAO and Winchester syndrome. J Bone Miner Res. 2007 Feb;22(2):329-33.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 242
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 23 Dec 2020